CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02450591
NCT02450591N/ACompleted
CompareCT.gov

Pilot Study of Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Memorial Sloan Kettering Cancer Center·interventional·Posted May 21, 2015·Updated May 21, 2018

In Brief

A clinical study evaluating Erlotinib and Local Therapies for Oligometastatic Lung Adenocarcinoma. Completed, enrolled 4 participants across 7 sites.

Detailed Summary

This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOligometastatic Lung Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 21, 2015
Enrollment StartMay 14, 2015
Primary CompletionDec 11, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.1 years ago

Interventions

Erlotinibdrug

Local Therapiesother

Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy